¼ººó¼¾Æ®º´¿ø 2019³â Á¦30ȸ ´ëÇÑ°£ÇÐȸ Ãá°è Single Topic Symposium ¹× ÃÊÀ½ÆÄ Hands-on : 2019-03-09±³À°ÀÏÀÚ : 2019-03-09
±³À°Àå¼Ò : ¼ººó¼¾Æ®º´¿ø º°°ü6Ãþ ¼ººó¼¾Æ®È¦, ÃÊÀ½ÆÄ Hands-on ÀÌ·Ð:¼ººó¼¾Æ®º´¿ø ¾Ïº´¿ø 4Ãþ ±³À°½Ç, ½Ç±â: 2Ãþ ¼Òȱ⳻°ú ¿Ü·¡
±³À°ÁÖÁ¦ :
2019³â Á¦30ȸ ´ëÇÑ°£ÇÐȸ Ãá°è Single Topic Symposium ¹× ÃÊÀ½ÆÄ Hands-onÁÖÃÖ±â°ü : ´ëÇÑ°£ÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : °æ±â-ÀÎõÁöȸ
´ã´çÀÚ : ´ëÇÑ°£ÇÐȸ
¿¬¶ôó : 02-703-0051
À̸ÞÀÏ :
kasl@kams.or.kr ±³À°Á¾·ù : ³»°ú
Âü¼®¿¹»óÀοø : 300¸í
Èñ¸ÁÆòÁ¡ : 5Á¡
Áö¿ª :
°æ±âµµ±³À°½Ã°£ : 11 ½Ã°£ 15ºÐ
¼¼ºÎ¼ö°·á : 50,000¿ø
ºñ°í *»çÀüµî·Ï STS-ȸ¿ø, ÀüÀÓÀÇ. Àü°øÀÇ 20000¿ø/ºñȸ¿ø 30000¿ø STS+ÃÊÀ½ÆÄ Hands-on-ȸ¿ø, ÀüÀÓÀÇ, Àü°øÀÇ 40000¿ø/ºñȸ¿ø 50000¿ø *ÇöÀåµî·Ï STS-ȸ¿ø, ÀüÀÓÀÇ. Àü°øÀÇ 30000¿ø/ºñȸ¿ø 40000¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 03-09 ¼ººó¼¾Æ®º´¿ø ¾Ïº´¿ø 4Ãþ ±³À°½Ç 09:00~09:30 º¹ºÎ ÃÊÀ½ÆÄ ±âº» ½ºÄµ¹ý ±èÈñ¾ð(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 03-09 ¼ººó¼¾Æ®º´¿ø ¾Ïº´¿ø 2Ãþ ¼Òȱ⳻°ú ¿Ü·¡ 09:45~12:15 ÃÊÀ½ÆÄ Hands-on 1Â÷ À¯Á¤È¯, ÀÌÇѾÆ, À¯Á¤ÁÖ, ±è¤¤Å¼®, ±èÈñ¾ð, Á¶È¿Á¤(ÀÎÇÏÀÇ´ë, °í·ÁÀÇ´ë, ¼øõÇâÀÇ´ë, °¿øÀÇ´ë, °¡Å縯ÀÇ´ë, ¾ÆÁÖÀÇ´ë)
±³À°½Ã°£ 03-09 ¼ººó¼¾Æ®º´¿ø º°°ü6Ãþ ¼ººó¼¾Æ®È¦ 09:40~10:05 Cardiovascular risk in ALD and NAFLD: How to assess and manage? À庴±¹(°è¸íÀÇ´ë)
±³À°½Ã°£ 03-09 ¼ººó¼¾Æ®º´¿ø º°°ü6Ãþ ¼ººó¼¾Æ®È¦ 10:05~10:30 Optimal timing of liver transplantation for severe alcoholic hepatitis ÁÖµ¿Áø(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 03-09 ¼ººó¼¾Æ®º´¿ø º°°ü6Ãþ ¼ººó¼¾Æ®È¦ 10:30~10:55 HCC surveillance in non-cirrhotic patients with ALD and NAFLD ±èº¸Çö(±¹¸³¾Ï¼¾ÅÍ)
±³À°½Ã°£ 03-09 ¼ººó¼¾Æ®º´¿ø º°°ü6Ãþ ¼ººó¼¾Æ®È¦ 11:10~11:30 Immunopathogenesis of ALD ¹Ú¼öÇü(Ä«À̽ºÆ®)
±³À°½Ã°£ 03-09 ¼ººó¼¾Æ®º´¿ø º°°ü6Ãþ ¼ººó¼¾Æ®È¦ 11:30~11:50 Identification of novel therapeutic targets for NAFLD progression ÇÑ⿱(¿ø±¤ÀÇ´ë)
±³À°½Ã°£ 03-09 ¼ººó¼¾Æ®º´¿ø º°°ü6Ãþ ¼ººó¼¾Æ®È¦ 11:50~12:10 Crosstalk among nutrient, microbiome, and metabolites in ALD and NAFLD °í±¤Ç¥(¼¿ïÀÇ´ë)
±³À°½Ã°£ 03-09 ¼ººó¼¾Æ®º´¿ø º°°ü6Ãþ ¼ººó¼¾Æ®È¦ 12:10~12:30 Non-invasive assessment of hepatic steatosis and fibrosis in ALD and NAFLD ÀÌ¿µ¼±(°í·ÁÀÇ´ë)
±³À°½Ã°£ 03-09 ¼ººó¼¾Æ®º´¿ø ¾Ïº´¿ø 4Ãþ ±³À°½Ç 13:15~13:45 º¹ºÎ ÃÊÀ½ÆÄ °Ë»ç ½ºÄµ½ÃÀÇ Trouble Shooting ±è¼ø¼±(¾ÆÁÖÀÇ´ë)
±³À°½Ã°£ 03-09 ¼ººó¼¾Æ®º´¿ø ¾Ïº´¿ø 2Ãþ ¼Òȱ⳻°ú ¿Ü·¡ 14:00~16:30 ÃÊÀ½ÆÄ Hands-on 2Â÷ ±è¼ø¼±, ½Å½Â°¢, ÀÓ¼±¿µ, ¼ÛÁ¤Àº, ÀÌÀ¯¸², ¹ÚÁ¤±æ(¾ÆÁÖÀÇ´ë, °¡ÃµÀÇ´ë, °í·ÁÀÇ´ë, ´ë±¸°¡Å縯ÀÇ´ë, °æºÏÀÇ´ë, ¿µ³²ÀÇ´ë)
±³À°½Ã°£ 03-09 ¼ººó¼¾Æ®º´¿ø º°°ü6Ãþ ¼ººó¼¾Æ®È¦ 13:30~14:00 ALD : From basic to clinic Kenichi Ikejima(Juntendo University, Japan)
±³À°½Ã°£ 03-09 ¼ººó¼¾Æ®º´¿ø º°°ü6Ãþ ¼ººó¼¾Æ®È¦ 14:00~14:30 NAFLD in ASIA Vincent Wong(The Chinese Univ. of Hong Kong)
±³À°½Ã°£ 03-09 ¼ººó¼¾Æ®º´¿ø º°°ü6Ãþ ¼ººó¼¾Æ®È¦ 14:45~15:00 Effects of modest alcohol use and gender on NAFLD outcome ½Åµ¿Çö(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 03-09 ¼ººó¼¾Æ®º´¿ø º°°ü6Ãþ ¼ººó¼¾Æ®È¦ 15:00~15:15 Prognosis and management of acute on chronic liver failure according to etiology ¼Ûµµ¼±(°¡Å縯ÀÇ´ë)
Åä·Ð 03-09 ¼ººó¼¾Æ®º´¿ø º°°ü6Ãþ ¼ººó¼¾Æ®È¦ 15:15~15:45 Pannel discussion ±è»ó±Õ, ±è¿ø(¼øõÇâÀÇ´ë, ¼¿ïÀÇ´ë)
±³À°½Ã°£ 03-09 ¼ººó¼¾Æ®º´¿ø º°°ü6Ãþ ¼ººó¼¾Æ®È¦ 15:45~16:05 ALD cases À±¾ÆÀϸ°(ÀÎÁ¦ÀÇ´ë)
±³À°½Ã°£ 03-09 ¼ººó¼¾Æ®º´¿ø º°°ü6Ãþ ¼ººó¼¾Æ®È¦ 16:05~16:25 NAFLD cases Á¤½Â¿ø(¼øõÇâÀÇ´ë)